SEC Filing Summary: AmerisourceBergen Corporation (10-Q)
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for AmerisourceBergen Corporation (now Cencora, Inc.) for the fiscal quarter and nine months ended June 30, 2003. The Company is a leading national wholesale distributor of pharmaceutical products and related healthcare services, organized into two reportable segments: Pharmaceutical Distribution and PharMerica. The report covers operations following the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2003 | Nine Months Ended June 30, 2003 |
|---|---|---|
| Total Revenue | $12.42 billion | $37.02 billion |
| Operating Revenue (Excl. Bulk) | $11.48 billion | $33.80 billion |
| Gross Profit | $560.4 million | $1.66 billion |
| Operating Income | $228.2 million | $652.6 million |
| Net Income | $112.5 million | $321.7 million |
| Diluted EPS | $0.99 | $2.85 |
| Cash Flow from Operations | N/A | ($792.4 million) used |
| Total Debt | $2.30 billion | $2.30 billion |
| Cash and Equivalents | $224.8 million | $224.8 million |
Note: Operating margins for the nine months ended June 30, 2003 were 1.93% of operating revenue. Gross profit margin was 4.92%.
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 12% for the quarter and 13% for the nine-month period compared to the prior year, driven primarily by the Pharmaceutical Distribution segment.
- Bulk Deliveries: Bulk deliveries to customer warehouses decreased 30% in the quarter and 14% for the nine months, largely due to the conversion of bulk business into operating revenue.
- Profitability: Net income increased 25% for the quarter and 29% for the nine months. Operating income rose 25% and 24%, respectively, aided by reduced special items and improved expense ratios.
- Cash Flow: Operating activities used $792.4 million in cash for the nine months ended June 30, 2003, a significant shift from the $116.4 million generated in the prior year. This was primarily due to a $1.27 billion increase in merchandise inventories and a $249.4 million increase in accounts receivable.
- Debt Structure: Total debt increased to $2.30 billion from $1.82 billion at the end of the prior fiscal year. The Company issued $300 million in 7 1/4% senior notes in November 2002 and entered into a new $1.05 billion receivables securitization facility in July 2003.
Guidance, Outlook, and Management Commentary
- Acquisitions: The Company completed three significant acquisitions: Anderson Packaging Inc. ($100.1 million), US Bioservices Corporation ($160.2 million), and Bridge Medical, Inc. ($28.4 million). These were aimed at expanding packaging capabilities, specialty pharmaceutical services, and supply chain technology.
- Integration Synergies: Management expects to achieve approximately $150 million in annual synergies by the end of fiscal 2004 through the consolidation of the distribution network (targeting 30 facilities) and elimination of duplicate functions.
- Outlook: Pharmaceutical Distribution operating revenue growth is expected to be 11% to 12% in the fourth quarter of fiscal 2003, approximating 13% for the full fiscal year. Management anticipates that cash provided by operations in the fourth quarter will offset the cash used in the first nine months.
- Risks and Contingencies:
- Margin Pressure: Downward pressure on gross profit margins is expected to continue due to competitive pricing and customer mix changes.
- Legal Matters: The Company is involved in various lawsuits, including a contract dispute with Bracco Diagnostics Inc. regarding chargebacks and credits.
- Interest Rate Risk: The Company has significant variable-rate debt ($811 million) exposed to interest rate fluctuations.
Key Facts for Investor Verification
- Working Capital Usage: Verify the sustainability of the $792 million cash outflow from operations, driven by inventory buildup and receivables growth, and confirm the expectation of a cash inflow in Q4.
- Debt Refinancing: Confirm the status of the new $1.05 billion ABC Securitization Facility entered into in July 2003 and its impact on liquidity and interest costs.
- Acquisition Integration: Monitor the realization of the projected $150 million in annual synergies and the progress of facility consolidations.
- Customer Concentration: Review the impact of the loss of a large retail customer in March 2003 and the slowdown in the workers' compensation business growth rate.
- Contingent Payments: Track potential future cash outflows related to contingent payments for US Bioservices, Bridge Medical, and the physician management consulting company acquisition.